Osteoarthritis Patients Needed for Clinical Trial
The Andrews Institute for Orthopaedics & Sports Medicine is now accepting patients for a clinical trial of the nSTRIDE APS Kit, an investigative cell-based injection for treatment of osteoarthritis (OA) of the knee and associated symptoms.
According to the Centers for Disease Control and Prevention, OA is one of the top five causes of disability among non-institutionalized adults in the United States. The standard of care focuses on noninvasive treatment to manage symptoms but generally doesn’t prevent the disease from progressing.
Although patients with OA account for more than 90 percent of knee replacement surgeries, few patients with disabling OA are willing to consider total knee replacement, according to the journal Medicographia.
As OA is associated with an increase in inflammatory proteins, which contribute to cartilage breakdown, the nSTRIDE APS Kit focuses on inhibiting inflammation. Using the patient’s own blood, it produces an autologous protein solution (APS) that is high in anti-inflammatory proteins and growth factors. The solution is injected into the knee joint, with the goal of promoting healing.
Andrews Institute was chosen as an investigational site for a double-blind clinical trial studying the use of the nSTRIDE APS Kit in those with painful osteoarthritis in one knee. Patients who meet eligibility requirements will be randomly assigned to receive an injection of the protein solution or saline, and patients will not know which injection they received. All of the study procedures and risks associated with the study will be discussed with potential candidates before a decision to participate is made. Patients may or may not benefit from taking part in the trial, but information learned may help patients with osteoarthritis in the future. For individuals who cannot fulfill the requirements of the study, Andrews Institute offers other treatment options for managing OA symptoms.